modelEtoposide

Diagram of Etoposide

Extends from Pharmacolibrary.Drugs.ATC.L.L01CB01.

Information

name:Etoposide
ATC code:L01CB01
route:intravenous
compartments:2
dosage:100mg
volume of distribution:7.6L
clearance:1.05L/h
other parameters in model implementation

Etoposide is a topoisomerase II inhibitor used as an antineoplastic agent for the treatment of various malignancies including small-cell lung cancer, testicular cancer, lymphoma, and leukemia. It is commonly administered intravenously or orally and is still approved and widely used in cancer chemotherapy.

Pharmacokinetics

Pharmacokinetics reported in adult cancer patients following intravenous administration; large multicenter population PK study.

References

  1. Reif, S, et al., & Jaehde, U (2002). Population pharmacokinetics of etoposide. International journal of clinical pharmacology and therapeutics 40(12) 578–579. DOI:10.5414/cpp40578 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12503821

  2. Nguyen, L, et al., & Canal, P (1998). Population pharmacokinetics of total and unbound etoposide. Cancer chemotherapy and pharmacology 41(2) 125–132. DOI:10.1007/s002800050718 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9443625

  3. Cheng, Y, et al., & Zhou, L (2024). Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES). Lung cancer (Amsterdam, Netherlands) 188 107455–None. DOI:10.1016/j.lungcan.2023.107455 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38224653

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)